Study identifies antidepressants that get patients well and keep them well
Worldwide, nearly 6% of people experience depression. Many of them continue taking antidepressants after achieving symptomatic improvement, among other reasons to prevent a relapse of depression. An international team of researchers investigated which antidepressants, if any, can not only get patients well but also keep them well (sustained response).
Nearly 6% of the global population suffers from depression, a condition that often persists even after patients begin taking antidepressants to alleviate their symptoms. An international research team has conducted a comprehensive study to determine which antidepressants are not only effective in the short term, but also maintain their therapeutic benefits over the long term.
The findings, published in The Lancet Psychiatry, indicate that certain medications may prove more beneficial for sustained response compared to others.
Utilizing data from 115 randomized clinical trials involving more than 30,000 patients, researchers compared 20 different antidepressants, including the widely used fluoxetine. The study revealed that three antidepressants—escitalopram, agomelatine, and duloxetine—exhibited superior performance in maintaining remission of depressive symptoms over extended periods of treatment. These three medications outperformed fluoxetine in terms of long-term effectiveness.
First author Paul van Haaren highlighted that escitalopram, which is already commonly prescribed, emerged as the most effective antidepressant for long-term depression management. However, agomelatine, while effective, carries a risk of liver failure—a potential side effect that must be carefully considered. Duloxetine, less frequently prescribed as a first-line treatment, also demonstrated positive results in maintaining remission.
The study's lead researcher, Eric Ruhé, professor of difficult-to-treat depression at Radboud University Medical Center, noted that the findings could influence future treatment guidelines. However, he emphasized that prescribers must weigh the benefits and potential side effects of each medication, as individual patient circumstances vary.
This research underscores the importance of selecting an antidepressant that not only alleviates symptoms but also minimizes risks, ultimately ensuring that patients remain well in the long run.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
